Loading…
Updated Drug Labeling for Patient Safety Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
58pct
2d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
Updated Drug Labeling for Patient Safety Act This bill allows generic drug manufacturers to revise labels with updated safety information that differs from the referenced brand-name drug.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2023 · fourth_quarter · Pharmacy
Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. Labeling of Generic Drugs and Biosimilars. H.R.4134/S.2886: Updated Drug Labeling for Patient Safety Act. Hickenlooper Safe Harbor for Skinny Labeling. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. S.2510: RAPID Reserve Act. Drug Shortages. Stop Drug Shortages Act of 2023. H.R.405: Essential Medicines Strategic Stockpile Act of 2023. S.2305: Biosimilar Red Tape Eliminations Act. FDA Inspections. Process issues regarding third-party contract to assess drug quality. Inflation Reduction Act (IRA) Implementation. H.R.3561: PATIENT Act of 2023. H.R.3793: Ensuring Access to Lifesaving Drugs Act of 2023. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $610,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
No bill number. Discussed medication overdoses. S.1250, the Drug Price Transparency for Consumers Act of 2023. No bill number. Discussed Medicare drug price negotiation. No bill number. Discussed Medicare Prescription Payment Plan (MPPP) program. H.R. 4134, the Updated Drug Labeling for Patient Safety Act. S.2886, Patient Safety and Generic Labeling Improvement Act. H.R. 5378, the Lower Costs, More Transparency Act. S. 1967, the Patients Before Middleman (PBM) Act. S.2973, the Modernizing and Ensuring PBM Accountability Act. S.127, the Pharmacy Benefit Manager (PBM) Transparency Act of 2023. S. 79, the Interagency Patent Coordination and Improvement Act of 2023. S. 113, the Prescription Pricing for the People Act of 2023. S. 142, the Preserve Access to Affordable Generics and Biosimilars Act of 2023. S. 148, the Stop STALLING Act. S. 150, the Affordable Prescriptions for Patients Act of 2023. S. 2780, the Medication Affordability and Patent Integrity Act. S. 1339, the Pharmacy Benefit Manager Reform Act.
Client expense: $3,890,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · third_quarter · Pharmacy
Prescription Drug Costs. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. S.1128: Ensuring Access to Generic Medications Act. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R.4692/S.574: Increasing Prescription Drug Competition Act. H.R.1790: Biologics Competition Act of 2023. Labeling of Generic Drugs and Biosimilars. H.R.4134/S.2886: Updated Drug Labeling for Patient Safety Act Hickenlooper Safe Harbor for Skinny Labeling. S.775: Increasing Transparency in Generic Drug Applications Act. S.2510: RAPID Reserve Act. Drug Shortages. END Drug Shortages Act of 2023. Stop Drug Shortages Act. H.R.3008/S.2362: Drug Shortage Prevention Act of 2023. H.R. 3810: Drug Origin Transparency Act of 2023. Stockpile of Generic Drugs. Same Strength Requirement for Biosimilars. Biosimilar Red Tape Eliminations Act. Expediting Competitive Biosimilar Competition. FDA Inspections. Shaheen-Cassidy Citizen Petition Legislation. Guthrie Priority Review Voucher. Inflation Reduction Act (IRA) Implementation. H.R.3561: PATIENT Act of 2023. Trusted Partners in Medical Supply Chains. S.2364: MAPS Act. Dunn DeLauro Valisure and Department of Defense Agreement. H.R.3793: Ensuring Access to Lifesaving Drugs Act of 2023. H.R.167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Client expense: $440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
No bill number. Discussed medication overdoses. S.1250, the Drug Price Transparency for Consumers Act of 2023. No bill number. Discussed Medicare drug price negotiation. No bill number. Discussed Medicare Prescription Payment Plan (MPPP) program. H.R. 4134, the Updated Drug Labeling for Patient Safety Act. S.2886, Patient Safety and Generic Labeling Improvement Act. H.R. 5378, the Lower Costs, More Transparency Act. S. 1967, the Patients Before Middleman (PBM) Act. S.2973, the Modernizing and Ensuring PBM Accountability Act. S.127, the Pharmacy Benefit Manager (PBM) Transparency Act of 2023. S. 79, the Interagency Patent Coordination and Improvement Act of 2023. S. 113, the Prescription Pricing for the People Act of 2023. S. 142, the Preserve Access to Affordable Generics and Biosimilars Act of 2023. S. 148, the Stop STALLING Act. S. 150, the Affordable Prescriptions for Patients Act of 2023. S. 2780, the Medication Affordability and Patent Integrity Act. S. 1339, the Pharmacy Benefit Manager Reform Act.
Client expense: $3,890,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office